Avexitide
- Generic Name
- Avexitide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C149H234N40O47S
- CAS Number
- 133514-43-9
- Unique Ingredient Identifier
- 5313W10MYT
- Background
Avexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia).
- Associated Conditions
- -
- Associated Therapies
- -
Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Dr. Tracey McLaughlin, MD
- Target Recruit Count
- 25
- Registration Number
- NCT04652479
- Locations
- 🇺🇸
Clinical and Translational Research Unit, Palo Alto, California, United States
The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D
- Conditions
- Interventions
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 15
- Registration Number
- NCT03246451
- Locations
- 🇩🇰
Center for Diabetes Research, Gentofte, Copenhagen, Denmark
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 15
- Registration Number
- NCT03241303
- Locations
- 🇩🇰
Center for Diabetesresearch, Hellerup, Denmark
Cardiovascular Effects of GLP-1 Receptor Activation
- Conditions
- Interventions
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 329
- Registration Number
- NCT03101930
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Tracey McLaughlin
- Target Recruit Count
- 9
- Registration Number
- NCT02996812
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Regulation of Insulin Secretion by the GLP-1 Receptor
- Conditions
- Interventions
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 6
- Registration Number
- NCT02844907
- Locations
- 🇺🇸
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States
Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Tracey McLaughlin
- Target Recruit Count
- 10
- Registration Number
- NCT02550145
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Ghrelin Effect on Beta Cell Function in Health and Disease
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- David Dalessio
- Target Recruit Count
- 30
- Registration Number
- NCT01729299
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio, United States
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Diva De Leon
- Target Recruit Count
- 14
- Registration Number
- NCT00835328
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.